4/12/2010

Synereca Pharmaceuticals, a startup formed by the University of North Carolina at Chapel Hill, licensed rights to use a professor's research on potential treatments for antibiotic-resistant bacteria. The company plans to develop drugs that inhibit the RecA enzyme, which plays an important role in antibiotic resistance.

Related Summaries